Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 01, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details changes in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- February 22, 2007: Holdings decreased from 16,282,764 to 16,249,606 ADRs at an average price of $57.10.
- February 23, 2007: Holdings increased from 16,249,606 to 16,282,040 ADRs at an average price of $56.36.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for employees and former employees, and that Directors Dr. J P Garnier and Dr. M M Slaoui are potentially interested in the shares held in the fund in the same capacity as other employees.
Investor Verification Points
- Verify the total aggregate holdings of the GlaxoSmithKline US Retirement Savings Plan to understand the net impact of the reported movements.
- Confirm the specific beneficial ownership status of Directors Dr. J P Garnier and Dr. M M Slaoui relative to the Plan's holdings.
- Review the company's Form 20-F for comprehensive financial data, as this Form 6-K does not contain financial statements.